Abstract
As the pharma industry continues to experience rising research costs, drug
failures and low returns on investment, companies who are increasingly facing
major patent expiries and scarcely populated late-stage pipelines have
accelerated efforts to enhance the speed and efficiency of drug research.
Translational science has emerged as a concept that is set to revolutionise
the traditional R&D paradigm by integrating drug discovery and development,
areas with previously limited interaction. The primary goals of this approach
are to terminate unsuccessful compounds earlier in their development, improve
confidence in human drug targets and enhance cost-effective decision-making.
Translational Medicine in Biopharmaceutical R&D is a new report published by
Business Insights that examines how translational medicine can positively
influence the impact of biomarkers, innovations in clinical trial designs and
the IT systems that support these functions. The report will identify how data
generated from pre-clinical studies and clinical trials can be used
synergistically between lab and clinic to enhance success rates and improve
' go/no-go' decision making. The strategies adopted by pharma companies to
incorporate such initiatives are evaluated and potential cost-savings are
assessed. This report will also highlight recent regulatory shifts in
biomarker development and application, in addition to investigating the
development of adaptive and seamless trial designs and micro-dosing. Discover
the benefits of translational medicine, evaluate the strategies used by R&D
organisations to implement translational methods and identify the innovative
technologies central to efficiency gains with this new report...
| 
View Cart
